TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02239081

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for CTP-730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for CTP-730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for CTP-730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for CTP-730
Study: NCT01417702

Intervention type: DEVICE
Intervention: High-definition white light endoscopy and i-Scan
Description: Patients will undergo advanced endoscopic imaging. Findings will be compared to histopathological and clinical results.

Intervention type: DEVICE
Intervention: High-definition white light endoscopy and i-Scan
Description: Patients will undergo advanced endoscopic imaging. Findings will be compared to histopathological and clinical results.

Intervention type: DEVICE
Intervention: High-definition white light endoscopy and i-Scan
Description: Patients will undergo advanced endoscopic imaging. Findings will be compared to histopathological and clinical results.

Intervention type: DEVICE
Intervention: High-definition white light endoscopy and i-Scan
Description: Patients will undergo advanced endoscopic imaging. Findings will be compared to histopathological and clinical results.
Study: NCT01064882

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bimatoprost ophthalmic solution 0.005%
Description: One drop applied to a sterile single-use-per-eye applicator and applied to upper eyelid margins (where the eyelashes meet the skin)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bimatoprost ophthalmic solution 0.015%
Description: One drop applied to a sterile single-use-per-eye applicator and applied to upper eyelid margins (where the eyelashes meet the skin)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bimatoprost ophthalmic solution 0.03%
Description: One drop applied to a sterile single-use-per-eye applicator and applied to upper eyelid margins (where the eyelashes meet the skin)
Study: NCT03258502

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RV521
Description: RV521 drug in capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo in capsules
Study: NCT04786483

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laughter Theraphy
Description: Laughter therapy will be applied for 60 minutes, 10 sessions, 2 days a week. The therapy, which starts with the stimulation of the acupuncture points in the palm and acquaintance with hand clapping for an average of 10 minutes, continues with deep breathing and breathing exercises that include diaphragmatic breathing. The childish games section, which is played to reveal and trigger simulated laughter, is the section where laughter starts as if and turns into reality. The last part is the part where the group makes eye contact for no reason and for no reason, and laughs for at least 3 minutes unconditionally. In the last part, wish meditation and relaxation sessions are performed.
Study: NCT04648852

Intervention type: OTHER
Intervention: Heart failure risk estimation
Description: Evaluation by heart failure risk score

Intervention type: OTHER
Intervention: Heart failure risk estimation
Description: Evaluation by heart failure risk score
Study: NCT03015870

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vocal exercise with real-time feedback
Description: The feedback intervention will use iPads pre-installed with a PDF of vocal exercises for the full duration of the study and with an app which will provide tailored feedback regarding pitch, loudness, and duration of phonation during practice sessions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Vocal exercise with recording
Description: The recording intervention will use an iPad pre-installed with the PDF of vocal exercises for the full duration of the study, but no feedback app.Participants audio record self while performing vocal exercises
Study: NCT06289023

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: HA-WBRT-SIB
Description: A total dose of 30-36 Gy delivered in 18-20 fractions to the whole brain (CTV), while the dose to the GTV were boosted to 44 Gy-52 Gy in 18-20 fractions, ﬁve times a week.
Study: NCT01016223

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Beclomethasone dipropionate
Description: Beclomethasone dipropionate 80 mcg two puffs twice daily for 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Matched placebo swallowed two puffs twice daily
Study: NCT00420147

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: wedged inshoe orthosis
Description: Treatment subjects were prescribed an inshoe wedged orthosis

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: neutral inshoe orthosis
Description: Control subjects were prescribed a neutral inshoe orthosis
Study: NCT00957996

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peramivir
Description: 300 mg twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peramivir
Description: 600 mg once daily
Study: NCT00066378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anastrozole

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: anastrozole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gefitinib
Study: NCT05584813

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypobaric Hypoxia
Description: The Waggoner Computerized Color Vision Test (WCCVT) and the Waggoner D-15 (WC-D15) were performed by 54 healthy volunteers in a decompression chamber.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypobaric Hypoxia
Description: The Waggoner Computerized Color Vision Test (WCCVT) and the Waggoner D-15 (WC-D15) were performed by 54 healthy volunteers in a decompression chamber.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypobaric Hypoxia
Description: The Waggoner Computerized Color Vision Test (WCCVT) and the Waggoner D-15 (WC-D15) were performed by 54 healthy volunteers in a decompression chamber.
Study: NCT02809807

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: measurement of the work of breathing
Description: We have been evaluating breathing patterns, index of respiratory efforts and blood gases in all randomized conditions. Airway pressure, inspiratory and expiratory flows have been measured. An esophageal catheter has been introduced at the beginning of the study to measure esophageal pressure (Peso) and calculate indexes of respiratory effort (PTPeso, WOB). SpO2 has been continuously measured and capillary blood bases were drawn at the end of each condition. Comfort has also been assessed. FreeO2 System has been used and pre-programmed in accordance with the patient SpO2 target zone for potential correction of the hypoxemia occurrences. Differences among randomized conditions are one without gas mask as for the baseline and two with gas masks but different canisters.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: measurement of the work of breathing
Description: We have been evaluating breathing patterns, index of respiratory efforts and blood gases in all randomized conditions. Airway pressure, inspiratory and expiratory flows have been measured. An esophageal catheter has been introduced at the beginning of the study to measure esophageal pressure (Peso) and calculate indexes of respiratory effort (PTPeso, WOB). SpO2 has been continuously measured and capillary blood bases were drawn at the end of each condition. Comfort has also been assessed. FreeO2 System has been used and pre-programmed in accordance with the patient SpO2 target zone for potential correction of the hypoxemia occurrences. Differences among randomized conditions are one without gas mask as for the baseline and two with gas masks but different canisters.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: measurement of the work of breathing
Description: We have been evaluating breathing patterns, index of respiratory efforts and blood gases in all randomized conditions. Airway pressure, inspiratory and expiratory flows have been measured. An esophageal catheter has been introduced at the beginning of the study to measure esophageal pressure (Peso) and calculate indexes of respiratory effort (PTPeso, WOB). SpO2 has been continuously measured and capillary blood bases were drawn at the end of each condition. Comfort has also been assessed. FreeO2 System has been used and pre-programmed in accordance with the patient SpO2 target zone for potential correction of the hypoxemia occurrences. Differences among randomized conditions are one without gas mask as for the baseline and two with gas masks but different canisters.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gas Mask
Description: Differences among randomized conditions are one without gas mask as for the baseline and two with gas masks but different canisters.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gas Mask
Description: Differences among randomized conditions are one without gas mask as for the baseline and two with gas masks but different canisters.
Study: NCT02414802

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: catheter-directed thrombolysis
Description: catheter-directed thrombolysis will be used in both arms

Intervention type: DRUG
Group type: OTHER
Intervention: low-molecular-weight heparin calcium
Description: anticoagulation therapy will be administered via subcutaneous injection of low-molecular-weight heparin calcium (LMWH-Ca 5,000 U/12 h) in both arms at discharge

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low-molecular-weight heparin calcium
Description: anticoagulation therapy will be administered via subcutaneous injection of low-molecular-weight heparin calcium (LMWH-Ca 5,000 U/12 h) in both arms at discharge

Intervention type: DRUG
Group type: OTHER
Intervention: urokinase
Description: A total of 100,000 units urokinase once every 4-6 hours will be used during catheter-directed thrombolysis therapy
Study: NCT03864341

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Referral to homelessness prevention services
Description: Referral to Homebase homelessness prevention services offered by community-based organizations in NYC

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Substance use services
Description: Referral to substance use services (SBIRT and peer counselor/social work contact) available at Bellevue Hospital

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Follow-up
Description: Follow-up to assist participants in receiving homelessness prevention services
Study: NCT03353142

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Equal Breathing
Description: * Blood pressure recorded at baseline, immediately pre- and post-trial~* Maximum Tolerable Breathing Ratio: Test run to determine the maximum tolerable time for inhalation and exhalation.~* PRESSURE TOLERANCE: Pressure algometer device used to determine pain pressure tolerance. It will be applied to the first dorsal interosseous and deltoid, and pain pressure tolerance will be measured and recorded. Pressure will be applied at 1kg per second until the patient indicates that the pressure has become painful. Pain pressure tolerance will be performed 3 times at each anatomical location and an average will be determined for each location.~* TRIAL: Participants will begin 5 minutes of Equal Breathing at their maximum tolerable equal breathing ratio that was previously determined. Immediately after 5 minutes of breathing, the pain pressure tolerance will be measured using pressure algometry
Study: NCT02414802

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: urokinase
Description: A total of 100,000 units urokinase once every 4-6 hours will be used during catheter-directed thrombolysis therapy
Study: NCT03305809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3154207
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3154207
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3154207
Description: Administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally.
Study: NCT01742845

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided administration of ropivacaine 4.75 mg/ml

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: landmark based superfical ropivacaine 4.75 mg/ml injection
Study: NCT03469492

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: Insulin regimens will be adjusted on a weekly basis as needed to achieve a target blood glucose level.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: Insulin regimens will be adjusted on a weekly basis as needed to achieve a target blood glucose level.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: exercise
Description: Exercise in accordance to the guidelines established by the American Diabetes Association.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: exercise
Description: Exercise in accordance to the guidelines established by the American Diabetes Association.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dietary counseling
Description: Dietary counseling in accordance to the guidelines established by the American Diabetes Association.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dietary counseling
Description: Dietary counseling in accordance to the guidelines established by the American Diabetes Association.
Study: NCT02507687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimatoprost SR
Description: Bimatoprost SR is a biodegradable, sustained-release, preservative-free bimatoprost implant, preloaded in an applicator for administration. The Bimatoprost SR implant is injected into the anterior chamber via the corneal limbus using the prefilled applicator.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimatoprost SR
Description: Bimatoprost SR is a biodegradable, sustained-release, preservative-free bimatoprost implant, preloaded in an applicator for administration. The Bimatoprost SR implant is injected into the anterior chamber via the corneal limbus using the prefilled applicator.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimatoprost SR
Description: Bimatoprost SR is a biodegradable, sustained-release, preservative-free bimatoprost implant, preloaded in an applicator for administration. The Bimatoprost SR implant is injected into the anterior chamber via the corneal limbus using the prefilled applicator.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimatoprost SR
Description: Bimatoprost SR is a biodegradable, sustained-release, preservative-free bimatoprost implant, preloaded in an applicator for administration. The Bimatoprost SR implant is injected into the anterior chamber via the corneal limbus using the prefilled applicator.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sham Bimatoprost SR
Description: Sham bimatoprost SR performed using the same procedure as for Bimatoprost SR using an needleless applicator that touches the eye at the area of insertion but does not deliver an implant into the anterior chamber.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sham Bimatoprost SR
Description: Sham bimatoprost SR performed using the same procedure as for Bimatoprost SR using an needleless applicator that touches the eye at the area of insertion but does not deliver an implant into the anterior chamber.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sham Bimatoprost SR
Description: Sham bimatoprost SR performed using the same procedure as for Bimatoprost SR using an needleless applicator that touches the eye at the area of insertion but does not deliver an implant into the anterior chamber.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sham Bimatoprost SR
Description: Sham bimatoprost SR performed using the same procedure as for Bimatoprost SR using an needleless applicator that touches the eye at the area of insertion but does not deliver an implant into the anterior chamber.
Study: NCT04373850

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home Visit
Description: Physical exam, medication dose titration
Study: NCT04720950

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 1 hour of exercise on a motorised treadmill at 70% maximal heart rate

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 1 hour of exercise on a motorised treadmill at 70% maximal heart rate
Study: NCT00729040

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stepping Up to Health
Description: Internet-mediated walking program with pedometers, goal-setting and tailored messaging

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stepping Up to Health
Description: Internet-mediated walking program with pedometers, goal-setting and tailored messaging
Study: NCT01187264

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: once weekly for a total duration of 12 weeks or earlier till patient achieves PASI 75

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: once weekly for a total duration of 12 weeks or earlier till patient achieves PASI 75
Study: NCT02515084

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET
Description: A FDG PET scan and a diffusion-weighted Magnetic Resonance Imaging will be performed to compare the efficacy to diagnose relapse in thyroid carcinoma

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI imaging
Study: NCT03863691

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amisulpride 300 MG
Description: A single dose of 300 mg amisulpride that looks identical to placebo control capsules.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: A placebo capsule with no inert pharmacological effect. Looks identical to the amisulpride capsules.
Study: NCT00700154

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Insulin infusion
Description: The infusion, a fast acting insulin analog in 1 Unit/ml of NaCl, starts prior the surgery the operation day for all patients and stops during the postoperative care in the control group (conventional therapy), the intervention group continues for three full days with insulin infusion. After the transition day (the fourth day) multiple doses of mixinsulin continues until the study ends 4 weeks after the randomization.
Study: NCT00535392

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Description: Intravenous 100 mg/mL, twice a day, maximum of 4 days~Subjects on oral levetiracetam at study entry receive the same intravenous (IV) dosage (mg-for-mg) to their oral dose.~Dosage for subjects not on levetiracetam at study entry was based on weight: if \<50 kg, the dose was 20 mg/kg/day (10 mg/kg/day twice daily); if weight ≥ 50 kg, the dose of levetiracetam intravenous (LEV IV) was 1000 mg/day (500 mg twice daily).
Study: NCT03818555

Intervention type: OTHER
Group type: OTHER
Intervention: Sebacia Microparticles Treatment
Description: Sebacia Microparticles procedure involving microparticles and 1064 nm laser. Three treatment procedures over a two-week period.
Study: NCT03954717

Intervention type: BEHAVIORAL
Intervention: Shepherd CAN DO Program
Description: CAN DO Shepherd is a four-day participatory program held at the Shepherd Center, in Atlanta, Georgia or people with MS. The four-day program comprises evidence-based, comprehensive, and personalized educational and experiential opportunities aimed at empowering and enabling a person with MS to live a health life beyond their MS.

Intervention type: BEHAVIORAL
Intervention: Shepherd CAN DO Program
Description: CAN DO Shepherd is a four-day participatory program held at the Shepherd Center, in Atlanta, Georgia or people with MS. The four-day program comprises evidence-based, comprehensive, and personalized educational and experiential opportunities aimed at empowering and enabling a person with MS to live a health life beyond their MS.
Study: NCT02507687

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Selective Laser Trabeculoplasty
Description: SLT is a laser procedure that targets the melanin, or pigment, in specific cells of the eye.~An ophthalmologist performed 360 degrees of SLT using a standardized method.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Selective Laser Trabeculoplasty
Description: SLT is a laser procedure that targets the melanin, or pigment, in specific cells of the eye.~An ophthalmologist performed 360 degrees of SLT using a standardized method.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Selective Laser Trabeculoplasty
Description: SLT is a laser procedure that targets the melanin, or pigment, in specific cells of the eye.~An ophthalmologist performed 360 degrees of SLT using a standardized method.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Selective Laser Trabeculoplasty
Description: SLT is a laser procedure that targets the melanin, or pigment, in specific cells of the eye.~An ophthalmologist performed 360 degrees of SLT using a standardized method.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sham Selective Laser Trabeculoplasty
Description: Sham SLT is performed on the contralateral eye using the same method as for SLT, with the exception that the laser is not switched to the active state.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sham Selective Laser Trabeculoplasty
Description: Sham SLT is performed on the contralateral eye using the same method as for SLT, with the exception that the laser is not switched to the active state.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sham Selective Laser Trabeculoplasty
Description: Sham SLT is performed on the contralateral eye using the same method as for SLT, with the exception that the laser is not switched to the active state.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sham Selective Laser Trabeculoplasty
Description: Sham SLT is performed on the contralateral eye using the same method as for SLT, with the exception that the laser is not switched to the active state.
Study: NCT02331810

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR113244
Description: Pharmaceutical form:solution for injection Route of administration: subcutaneous

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Pharmaceutical form:solution for injection Route of administration: subcutaneous
Study: NCT00088543

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Thymoglobulin [Anti-Thymocyte Globulin (Rabbit)]
Description: total dose 4.5 mg/kg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Thymoglobulin [Anti-Thymocyte Globulin (Rabbit)]
Description: total dose 8.5 mg/kg